Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
201 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Major Depressive Disorder - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Major Depressive Disorder - Pipeline Review, H1 2015', provides an overview of the Major Depressive Disorder's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Major Depressive Disorder Overview 8 Therapeutics Development 9 Pipeline Products for Major Depressive Disorder - Overview 9 Pipeline Products for Major Depressive Disorder - Comparative Analysis 10 Major Depressive Disorder - Therapeutics under Development by Companies 11 Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes 15 Major Depressive Disorder - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Major Depressive Disorder - Products under Development by Companies 20 Major Depressive Disorder - Products under Investigation by Universities/Institutes 24 Major Depressive Disorder - Companies Involved in Therapeutics Development 25 Actavis plc 25 Alkermes Plc 26 Angelini Group 27 Azevan Pharmaceuticals, Inc. 28 BioCrea GmbH 29 Bristol-Myers Squibb Company 30 Cerecor Inc. 31 e-Therapeutics plc 32 Edgemont Pharmaceuticals, LLC 33 Eli Lilly and Company 34 Euthymics Bioscience, Inc. 35 F. Hoffmann-La Roche Ltd. 36 GlaxoSmithKline plc 37 H. Lundbeck A/S 38 Hua Medicine Ltd. 39 Intas Pharmaceuticals Ltd. 40 Intra-Cellular Therapies, Inc. 41 Jiangsu Hansoh Pharmaceutical Co., Ltd. 42 Johnson & Johnson 43 Lead Discovery Center GmbH 44 Luye Pharma Group Ltd. 45 Methylation Sciences Inc. 46 miCure Therapeutics Ltd. 47 Mitsubishi Tanabe Pharma Corporation 48 Naurex, Inc. 49 Neuralstem, Inc. 50 nLife Therapeutics, S.L. 51 Otsuka Holdings Co., Ltd. 52 Pherin Pharmaceuticals, Inc. 53 Reviva Pharmaceuticals Inc. 54 Richter Gedeon Nyrt. 55 Saniona AB 56 Sumitomo Dainippon Pharma Co., Ltd. 57 Sunovion Pharmaceuticals Inc. 58 Suven Life Sciences Ltd. 59 Trevena, Inc. 60 VistaGen Therapeutics , Inc. 61 Major Depressive Disorder - Therapeutics Assessment 62 Assessment by Monotherapy Products 62 Assessment by Combination Products 63 Assessment by Target 64 Assessment by Mechanism of Action 67 Assessment by Route of Administration 70 Assessment by Molecule Type 72 Drug Profiles 74 (aripiprazole + sertraline) - Drug Profile 74 (samidorphan + buprenorphine hydrochloride) - Drug Profile 75 amitifadine - Drug Profile 77 AN-788 - Drug Profile 79 aripiprazole - Drug Profile 80 AV-101 - Drug Profile 81 AVP-786 - Drug Profile 83 basimglurant - Drug Profile 85 brexpiprazole - Drug Profile 87 bupropion hydrochloride ER - Drug Profile 89 cariprazine - Drug Profile 90 CERC-301 - Drug Profile 92 desvenlafaxine succinate SR - Drug Profile 93 EDG-005 - Drug Profile 94 edivoxetine - Drug Profile 95 esketamine hydrochloride - Drug Profile 97 INASTR-001 - Drug Profile 99 ITI-007 - Drug Profile 100 lurasidone hydrochloride - Drug Profile 102 LY-03005 - Drug Profile 104 LY-2940094 - Drug Profile 105 MIN-117 - Drug Profile 106 miR-135 - Drug Profile 107 MSI-195 - Drug Profile 108 NLF-NEU - Drug Profile 109 NRX-1074 - Drug Profile 110 NSI-189 - Drug Profile 111 onabotulinumtoxin A - Drug Profile 112 PH-10 - Drug Profile 114 rapastinel - Drug Profile 115 RP-5063 - Drug Profile 117 SEP-363856 - Drug Profile 118 Small Molecule to Inhibit FKBP51 for Major Depressive Disorder - Drug Profile 119 Small Molecule to Target SLC6A15 for Major Depressive Disorder - Drug Profile 120 Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 121 Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile 122 Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 123 Small Molecules to Antagonize NR2B for Major Depression - Drug Profile 124 Small Molecules to Inhibit COMT for Cognitive Disorders - Drug Profile 125 SRX-246 - Drug Profile 126 SUVN-911 - Drug Profile 128 tedatioxetine - Drug Profile 129 tramadol hydrochloride - Drug Profile 131 trazodone hydrochloride - Drug Profile 133 TRV-250 - Drug Profile 134 vortioxetine hydrobromide - Drug Profile 135 Major Depressive Disorder - Recent Pipeline Updates 138 Major Depressive Disorder - Dormant Projects 178 Major Depressive Disorder - Discontinued Products 184 Major Depressive Disorder - Product Development Milestones 187 Featured News & Press Releases 187 Appendix 196 Methodology 196 Coverage 196 Secondary Research 196 Primary Research 196 Expert Panel Validation 196 Contact Us 196 Disclaimer 197
List of Tables
Number of Products under Development for Major Depressive Disorder, H1 2015 13 Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H1 2015 14 Number of Products under Development by Companies, H1 2015 16 Number of Products under Development by Companies, H1 2015 (Contd..1) 17 Number of Products under Development by Companies, H1 2015 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H1 2015 19 Comparative Analysis by Late Stage Development, H1 2015 20 Comparative Analysis by Clinical Stage Development, H1 2015 21 Comparative Analysis by Early Stage Development, H1 2015 22 Comparative Analysis by Unknown Stage Development, H1 2015 23 Products under Development by Companies, H1 2015 24 Products under Development by Companies, H1 2015 (Contd..1) 25 Products under Development by Companies, H1 2015 (Contd..2) 26 Products under Development by Companies, H1 2015 (Contd..3) 27 Products under Investigation by Universities/Institutes, H1 2015 28 Major Depressive Disorder - Pipeline by Actavis plc, H1 2015 29 Major Depressive Disorder - Pipeline by Alkermes Plc, H1 2015 30 Major Depressive Disorder - Pipeline by Angelini Group, H1 2015 31 Major Depressive Disorder - Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 32 Major Depressive Disorder - Pipeline by BioCrea GmbH, H1 2015 33 Major Depressive Disorder - Pipeline by Bristol-Myers Squibb Company, H1 2015 34 Major Depressive Disorder - Pipeline by Cerecor Inc., H1 2015 35 Major Depressive Disorder - Pipeline by e-Therapeutics plc, H1 2015 36 Major Depressive Disorder - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2015 37 Major Depressive Disorder - Pipeline by Eli Lilly and Company, H1 2015 38 Major Depressive Disorder - Pipeline by Euthymics Bioscience, Inc., H1 2015 39 Major Depressive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 40 Major Depressive Disorder - Pipeline by GlaxoSmithKline plc, H1 2015 41 Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H1 2015 42 Major Depressive Disorder - Pipeline by Hua Medicine Ltd., H1 2015 43 Major Depressive Disorder - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 44 Major Depressive Disorder - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 45 Major Depressive Disorder - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 46 Major Depressive Disorder - Pipeline by Johnson & Johnson, H1 2015 47 Major Depressive Disorder - Pipeline by Lead Discovery Center GmbH, H1 2015 48 Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H1 2015 49 Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H1 2015 50 Major Depressive Disorder - Pipeline by miCure Therapeutics Ltd., H1 2015 51 Major Depressive Disorder - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 52 Major Depressive Disorder - Pipeline by Naurex, Inc., H1 2015 53 Major Depressive Disorder - Pipeline by Neuralstem, Inc., H1 2015 54 Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H1 2015 55 Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 56 Major Depressive Disorder - Pipeline by Pherin Pharmaceuticals, Inc., H1 2015 57 Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 58 Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H1 2015 59 Major Depressive Disorder - Pipeline by Saniona AB, H1 2015 60 Major Depressive Disorder - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 61 Major Depressive Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 62 Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H1 2015 63 Major Depressive Disorder - Pipeline by Trevena, Inc., H1 2015 64 Major Depressive Disorder - Pipeline by VistaGen Therapeutics , Inc., H1 2015 65 Assessment by Monotherapy Products, H1 2015 66 Assessment by Combination Products, H1 2015 67 Number of Products by Stage and Target, H1 2015 69 Number of Products by Stage and Mechanism of Action, H1 2015 72 Number of Products by Stage and Route of Administration, H1 2015 75 Number of Products by Stage and Molecule Type, H1 2015 77 Major Depressive Disorder Therapeutics - Recent Pipeline Updates, H1 2015 142 Major Depressive Disorder - Dormant Projects, H1 2015 182 Major Depressive Disorder - Dormant Projects (Contd..1), H1 2015 183 Major Depressive Disorder - Dormant Projects (Contd..2), H1 2015 184 Major Depressive Disorder - Dormant Projects (Contd..3), H1 2015 185 Major Depressive Disorder - Dormant Projects (Contd..4), H1 2015 186 Major Depressive Disorder - Dormant Projects (Contd..5), H1 2015 187 Major Depressive Disorder - Discontinued Products, H1 2015 188 Major Depressive Disorder - Discontinued Products (Contd..1), H1 2015 189 Major Depressive Disorder - Discontinued Products (Contd..2), H1 2015 190
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
